Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
122 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibrosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis - Pipeline Review, H2 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape. Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 29, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Fibrosis - Overview 7 Fibrosis - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Fibrosis - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 21 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Fibrosis - Companies Involved in Therapeutics Development 28 Acceleron Pharma Inc 28 Aelis Farma SAS 28 Anima Biotech Ltd 28 Bristol-Myers Squibb Company 29 Cellmid Ltd 29 Clementia Pharmaceuticals Inc 30 Complexa Inc 30 Confo Therapeutics 31 EA Pharma Co Ltd 31 Five Prime Therapeutics Inc 31 Genfit SA 32 GlycoMimetics Inc 32 iBio Inc 33 Inception Sciences Inc 33 Isarna Therapeutics GmbH 34 Kadmon Corp LLC 34 Kalyra Pharmaceuticals Inc 34 Morphic Therapeutic Inc 35 Neumedicines Inc 35 Novartis AG 36 Palatin Technologies Inc 36 Proximagen Ltd 37 Redx Pharma Plc 37 Ribomic Inc 37 Scholar Rock Inc 38 SciFluor Life Sciences LLC 38 SK Chemicals Co Ltd 38 Symic Biomedical Inc 39 Fibrosis - Drug Profiles 40 ACE-2798 - Drug Profile 40 AEF-0118 - Drug Profile 41 AK-002 - Drug Profile 42 Antisense RNAi Oligonucleotide to Inhibit HSP47 for Fibrosis - Drug Profile 43 CAB-101 - Drug Profile 44 CALY-001 - Drug Profile 46 CWHM-12 - Drug Profile 47 Drugs for Fibrosis - Drug Profile 48 elafibranor - Drug Profile 49 G-XXX - Drug Profile 57 IB-DMD - Drug Profile 58 IBIOCFB-03 - Drug Profile 59 ISTH-1106 - Drug Profile 62 KL-01045 - Drug Profile 63 Monoclonal Antibodies for Fibrosis - Drug Profile 64 Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile 65 Monoclonal Antibody 2 for Fibrosis - Drug Profile 66 Monoclonal Antibody for Fibrotic Scar - Drug Profile 67 Monoclonal Antibody to Activate BMP7 for Fibrosis - Drug Profile 68 NCE-401 - Drug Profile 69 Neumomir - Drug Profile 70 NMIL-121 - Drug Profile 71 PAT-048 - Drug Profile 75 phenylbutyrate - Drug Profile 76 PL-5028 - Drug Profile 77 PRI-724 - Drug Profile 78 Proteins for Central Nervous System Disorders and Fibrosis - Drug Profile 80 RBM-003 - Drug Profile 81 RBM-007 - Drug Profile 82 SB-061 - Drug Profile 83 Small Molecule for Fibrosis - Drug Profile 85 Small Molecule for Fibrosis - Drug Profile 86 Small Molecule to Antagonize CCR2 and CCR5 for Fibrotic Diseases - Drug Profile 87 Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 88 Small Molecule to Inhibit MGAT2 for Metabolic Disorders and Fibrotic Diseases - Drug Profile 89 Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile 90 Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile 91 Small Molecules for Fibrosis - Drug Profile 92 Small Molecules for Fibrosis - Drug Profile 93 Small Molecules for Fibrosis - Drug Profile 94 Small Molecules for Fibrosis - Drug Profile 95 Small Molecules for Fibrosis - Drug Profile 96 Small Molecules for Fibrosis and Inflammatory Diseases - Drug Profile 97 Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 98 Small Molecules to Agonize GPCR for Fibrosis - Drug Profile 99 Small Molecules to Agonize RARG for Fibrosis - Drug Profile 100 Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile 101 Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 102 Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology - Drug Profile 103 SRI-31277 - Drug Profile 104 ST-2001 - Drug Profile 105 ST-2022 - Drug Profile 106 Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology - Drug Profile 107 TTX-330 - Drug Profile 108 X-165 - Drug Profile 109 XOMA-089 - Drug Profile 110 Fibrosis - Dormant Projects 111 Fibrosis - Product Development Milestones 114 Featured News & Press Releases 114 Appendix 117 Methodology 117 Coverage 117 Secondary Research 117 Primary Research 117 Expert Panel Validation 117 Contact Us 117 Disclaimer 118
List of Tables
Number of Products under Development for Fibrosis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Fibrosis - Pipeline by Acceleron Pharma Inc, H2 2017 Fibrosis - Pipeline by Aelis Farma SAS, H2 2017 Fibrosis - Pipeline by Anima Biotech Ltd, H2 2017 Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2017 Fibrosis - Pipeline by Cellmid Ltd, H2 2017 Fibrosis - Pipeline by Clementia Pharmaceuticals Inc, H2 2017 Fibrosis - Pipeline by Complexa Inc, H2 2017 Fibrosis - Pipeline by Confo Therapeutics, H2 2017 Fibrosis - Pipeline by EA Pharma Co Ltd, H2 2017 Fibrosis - Pipeline by Five Prime Therapeutics Inc, H2 2017 Fibrosis - Pipeline by Genfit SA, H2 2017 Fibrosis - Pipeline by GlycoMimetics Inc, H2 2017 Fibrosis - Pipeline by iBio Inc, H2 2017 Fibrosis - Pipeline by Inception Sciences Inc, H2 2017 Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017 Fibrosis - Pipeline by Kadmon Corp LLC, H2 2017 Fibrosis - Pipeline by Kalyra Pharmaceuticals Inc, H2 2017 Fibrosis - Pipeline by Morphic Therapeutic Inc, H2 2017 Fibrosis - Pipeline by Neumedicines Inc, H2 2017 Fibrosis - Pipeline by Novartis AG, H2 2017 Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017 Fibrosis - Pipeline by Proximagen Ltd, H2 2017 Fibrosis - Pipeline by Redx Pharma Plc, H2 2017 Fibrosis - Pipeline by Ribomic Inc, H2 2017 Fibrosis - Pipeline by Scholar Rock Inc, H2 2017 Fibrosis - Pipeline by SciFluor Life Sciences LLC, H2 2017 Fibrosis - Pipeline by SK Chemicals Co Ltd, H2 2017 Fibrosis - Pipeline by Symic Biomedical Inc, H2 2017 Fibrosis - Dormant Projects, H2 2017 Fibrosis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Fibrosis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
